Get the Stockscreener App
46.96
0.76%
-0.36
Halozyme Therapeutics Inc stock is traded at $46.96, with a volume of 4.28M.
It is down -0.76% in the last 24 hours and up +2.62% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$47.32
Open:
$47.03
24h Volume:
4.28M
Relative Volume:
2.55
Market Cap:
$5.97B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
24.98
EPS:
1.88
Net Cash Flow:
$392.71M
1W Performance:
-2.17%
1M Performance:
+2.62%
6M Performance:
-7.67%
1Y Performance:
+29.08%
1-Day Range:
$46.88
$48.20
1-Week Range:
$46.45
$49.60
52-Week Range:
$33.15
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
46.96 | 5.97B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Tidal Investments LLC Buys 14,947 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Sanctuary Advisors LLC Has $2.12 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.11 - MarketBeat
Halozyme Therapeutics' (HALO) Buy Rating Reiterated at HC Wainwright - MarketBeat
Wellington Management Group LLP Reduces Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
9 Analysts Have This To Say About Halozyme Therapeutics - Benzinga
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - MSN
Johnson & Johnson Rybrevant version rejected in US (JNJ:NYSE) - Seeking Alpha
Needle Free Drug Delivery Devices Market Industry Trends and Forecasts to 2035, Featuring Profiles of Halozyme, HNS, INOVIO Pharmaceuticals and Medical International Technology and PharmaJet - Yahoo Finance
How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% - Yahoo Finance
Geode Capital Management LLC Purchases 30,901 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Retirement Systems of Alabama Has $22.28 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Trading (HALO) With Integrated Risk Controls - Stock Traders Daily
World Investment Advisors LLC Acquires Shares of 57,526 Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Zacks Research Issues Optimistic Forecast for HALO Earnings - MarketBeat
Halozyme to Present at Upcoming Investor Conferences - The Eastern Progress Online
Q1 EPS Forecast for Halozyme Therapeutics Boosted by Analyst - MarketBeat
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer - The Eastern Progress Online
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock - MSN
Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? - Yahoo Finance
Hodges Capital Management Inc. Trims Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Pier Capital LLC - MarketBeat
Castleark Management LLC Takes $3.99 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Janus Henderson Group PLC Purchases 31,871 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now - Yahoo Finance
HALO vs. FOLD: Which Stock Is the Better Value Option? - Yahoo Finance
Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance
Erste Asset Management GmbH Invests $2.72 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
94,009 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Caisse DE Depot ET Placement DU Quebec - MarketBeat
Bridgewater Associates LP Has $659,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Phase 2 Data in Advanced Pancreas Cancer Featured in an Oral Presentation at ASCO - Marketscreener.com
Edgestream Partners L.P. Purchases 46,352 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Hantz Financial Services Inc. Invests $9.26 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
CreativeOne Wealth LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
San Diego’s Halozyme withdraws $2.1B Evotec bid, just one week after making offer - MSN
Halozyme abandons Evotec bid - Speciality Chemicals Magazine
Townsquare Capital LLC Boosts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Glenmede Trust Co. NA Acquires 109,283 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Seems To Use Debt Rather Sparingly - Simply Wall St
Fisher Asset Management LLC Has $18.55 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
RPg Family Wealth Advisory LLC Purchases New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Swedbank AB Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Halozyme CEO and CFO to Present at Major Healthcare Investor Conferences in December - StockTitan
Halozyme: Growth Amid Uncertainty After Failed Acquisition (Rating Downgrade) (HALO) - Seeking Alpha
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up - MSN
Halozyme abandons its €2bn pursuit of Evotec - pharmaphorum
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Intech Investment Management LLC - MarketBeat
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Oct 15 '24 |
Option Exercise |
18.15 |
10,000 |
181,455 |
183,756 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Oct 15 '24 |
Sale |
53.75 |
10,000 |
537,469 |
173,756 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Oct 16 '24 |
Sale |
53.26 |
10,000 |
532,590 |
173,756 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):